Patients | 56 | 125 | |
Age years | 56±14.6 | 61±12.4 | 0.011++ |
Female | 41 (73.2) | 67 (53.6) | 0.014§§ |
BMI kg·m−2 | 27.6±3.8 | 29.1±6.0 | 0.079++ |
Smokers (including ex-smokers) | 18 (32.1) | 73 (58.4) | 0.001§§ |
Smoking history pack-years | 7 (2–12) | 20 (10–32) | <0.001ƒƒ |
≥10 pack-years and post-BD FEV1/FVC <0.7¶ | 4 (7.1) | 29 (23.4) | 0.011§§ |
Pre-BD FEV1% pred | 92 (86–99) | 82 (70–93) | <0.001ƒƒ |
Pre-BD FEV1/FVC | 0.75 (0.70–0.79) | 0.73 (0.64–0.78) | 0.016ƒƒ |
Post-BD FEV1% pred | 96 (90–101) | 84 (75–96) | <0.001ƒƒ |
Post-BD FEV1/FVC | 0.77 (0.73–0.83) | 0.73 (0.65–0.79) | 0.002ƒƒ |
Blood eosinophils ×109·L−1 | 0.17 (0.12–0.28) | 0.18 (0.09–0.27) | 0.353ƒƒ |
Total IgE kU·L−1 | 51 (28–161) | 71 (24–172) | 0.617ƒƒ |
FeNO ppb | 12 (6–19) | 10 (5–18) | 0.392ƒƒ |
Blood neutrophils ×109·L−1 | 3.7 (3.0–4.6) | 3.9 (2.9–4.9) | 0.522ƒƒ |
Prescribed daily dose of ICS µg BDP | 751 (502–939) | 838 (664–1023) | 0.014ƒƒ |
Dispensed daily dose of ICS µg BDP | 411 (246–625) | 602 (354–838) | 0.002ƒƒ |
Daily SABA+ | 2 (3.6)### | 19 (15.2) | 0.024§§ |
Daily LABA+ | 18 (32.1) | 77 (61.6) | <0.001§§ |
Self-reported use of oral corticosteroid courses for asthma§ | 12 (21.4) | 48 (39.0) | 0.06§§ |
Dispensed oral corticosteroid for asthma per year mgƒ | 44 (0–127) | 92 (0–240) | 0.013ƒƒ |
Comorbidities | 1 (0–2) | 1 (0–3) | 0.057ƒƒ |
Co-medications (nonrespiratory) | 1 (0–4) | 2 (0–4) | 0.124ƒƒ |
AQ20 score | 2 (0–4) | 6 (3–9) | <0.001ƒƒ |
ACT score | 24 (22–25) | 20 (17–23) | <0.001ƒƒ |
Asthma-related visits to healthcare§,## | 12 (6–19) | 16 (10–26) | 0.014ƒƒ |
Atopy¶¶ | 27 (50.9) | 34 (30.6) | 0.016§§ |
≥1 hospital in-patient periods, asthma-related (unplanned)§ | 1 (1.8) | 15 (12.0) | 0.024§§ |